ClinicalTrials.gg
Not yet recruitingNCT07853053Updated Nov 5, 2026

DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer

A Phase 1 interventional study of Disitamab Vedotin and Toripalimab in Bladder Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 1, Interventional, and Treatment

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — 14 open to participants now, 14 under way, 1 of them phase 3. Urinary Bladder Neoplasms · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Started
2027
the only one that year
Phase 1
2 of 21
2 open now
Primary completion
2029-12
later than 13 of 13 live
Registered
21st of 21
by date

Among the 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the only one that started in 2027, is one of 2 in phase 1, reaches primary completion later than 13 of the 13 other live ones, and was the 21st registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

14 of the 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, or all of them as a file.
02

Study summary

This is a prospective, open-label, single-arm exploratory clinical study evaluating the efficacy and safety of disitamab vedotin (RC48) plus toripalimab with cetirizine and mecobalamin in patients with locally advanced unresectable or metastatic bladder cancer who have not received prior systemic therapy for advanced disease.

Disitamab vedotin is a HER2-targeted antibody-drug conjugate, and toripalimab is a PD-1 immune checkpoint inhibitor. Although antibody-drug conjugates have shown antitumor activity in urothelial cancer, treatment-related peripheral neuropathy may affect patients' quality of life and the ability to continue treatment. In this study, cetirizine and mecobalamin are incorporated as a supportive and preventive strategy to explore whether they may help reduce or delay treatment-related peripheral neuropathy while maintaining antitumor activity.

Approximately 10 to 20 participants will be enrolled. The primary outcomes are objective response rate according to RECIST v1.1 and the incidence of treatment-related Grade 2 or higher peripheral neuropathy. Secondary outcomes include overall safety, disease control rate, progression-free survival, and overall survival. Exploratory analyses will evaluate changes in the tumor immune microenvironment, including CD8-positive T-cell infiltration and activation, and their associations with treatment response and peripheral neuropathy.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Disitamab Vedotin
  • Toripalimab
  • Cetirizine
  • Mecobalamin
  • ADC-related Peripheral Neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agrees to participate in the study, is able to provide written , and is able to understand and comply with the study requirements and assessment schedule.
  2. Age ≥18 years, regardless of sex.
  3. or cytologically confirmed bladder urothelial carcinoma, including pure urothelial carcinoma or mixed bladder carcinoma with a predominant urothelial carcinoma component (≥50%), with clinically diagnosed unresectable locally advanced, recurrent, or disease that is not suitable for curative surgery or definitive radiotherapy.
  4. expression ≥1+ by immunohistochemistry, as determined at the local laboratory using a pretreatment tumor specimen.
  5. (ECOG) performance status of 0 or 1.
  6. Adequate organ function, as demonstrated by the following laboratory values obtained within 14 days before enrollment:

    a. The following hematologic criteria must be met without growth factor support within 14 days before sample collection: i. ≥1.5 × 10\^9/L; ii. count ≥90 × 10\^9/L; iii. ≥90 g/L. b. (INR) or activated partial thromboplastin time (aPTT) ≤1.5 × the (ULN).

    c. Total serum ≤1.5 × ULN; for participants with Gilbert syndrome or predominantly indirect hyperbilirubinemia of extrahepatic origin, total bilirubin must be ≤3 × ULN.

    d. (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤2.5 × ULN.

  7. At least one according to version 1.1.
  8. Any adverse events related to prior anticancer treatment must have recovered to Grade 0 or 1 before enrollment, except for clinically insignificant toxicities such as alopecia, pigmentation changes, or stable endocrine abnormalities controlled with replacement therapy.
  9. No peripheral neuropathy at enrollment. Participants with a history of peripheral neuropathy must have Grade 0 peripheral neuropathy at enrollment.
  10. Female participants of must have a negative pregnancy test before enrollment and agree to use effective during study treatment and for the protocol-specified period after the last dose. Male participants with partners of childbearing potential must also agree to use effective contraception.

Exclusion criteria

Exclusion Criteria:

  1. Prior systemic anticancer treatment for advanced, recurrent, or bladder cancer, including chemotherapy, immunotherapy, targeted therapy, antibody-drug conjugates (ADCs), or other anticancer agents.
  2. Prior treatment with disitamab vedotin, another -targeted ADC, or an MMAE-containing ADC; or a history of severe immune-related adverse events associated with prior treatment with , PD-L1, CTLA-4, or other immune checkpoint inhibitors.
  3. Known to disitamab vedotin, toripalimab, cetirizine, mecobalamin, or any component of these agents.
  4. Grade 2 or higher peripheral neuropathy, or a severe neurologic disorder that, in the investigator's judgment, may interfere with assessment of neurotoxicity, including but not limited to severe diabetic peripheral neuropathy, spinal cord compression, severe spinal canal stenosis, active neuritis, or demyelinating disease.
  5. Active or previously diagnosed disease that may worsen with PD-1 inhibitor therapy, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, vasculitis, autoimmune hepatitis, or multiple sclerosis.
  6. Receipt of a within 28 days before enrollment. Seasonal injectable influenza vaccines that are inactivated are permitted; intranasal live vaccines are not permitted.
  7. Active central nervous system metastases, , or carcinomatous meningitis. Participants with previously treated may be considered eligible if the lesions are stable, the participant is asymptomatic, have been discontinued or reduced to a low dose, and enrollment is considered safe by the investigator.
  8. Requirement for long-term high-dose corticosteroid therapy or other therapy that, in the investigator's judgment, may interfere with study treatment.
  9. abnormalities of potassium, sodium, or calcium; hypoalbuminemia; interstitial lung disease; noninfectious pneumonitis; or other uncontrolled systemic diseases that, in the investigator's judgment, may interfere with study treatment, including uncontrolled diabetes mellitus, hypertension, or cardiovascular disease. This includes active cardiac disease within 6 months before enrollment, such as severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, or ventricular arrhythmias requiring medical treatment.
  10. Untreated chronic infection or hepatitis B virus (HBV) carrier status with HBV DNA ≥500 IU/mL (2500 copies/mL). Participants who are inactive hepatitis B surface antigen carriers or who have stable active HBV infection after continuous antiviral therapy with HBV DNA \<500 IU/mL may be enrolled. HBV DNA testing is required only for participants who are positive for hepatitis B core antibody.
  11. Active infection. Participants with a negative hepatitis C virus (HCV) antibody test during screening, or those with a positive HCV antibody test but negative HCV RNA, may be enrolled. Participants with a positive HCV antibody test must undergo HCV RNA testing.
  12. History of immunodeficiency, including positive (HIV) testing or other acquired or congenital immunodeficiency disorders, or a history of stem cell transplantation or organ transplantation.
  13. Major surgery, definitive radiotherapy, or extensive palliative radiotherapy within 4 weeks before enrollment, or unresolved surgery- or radiotherapy-related toxicity above Grade 1.
  14. Another within the previous 5 years, except for malignancies that have been definitively treated and are considered to have a low risk of recurrence, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, low-risk prostate cancer, or adequately treated non-muscle-invasive bladder cancer.
  15. Pregnant or breastfeeding women.
  16. Drug or alcohol abuse, severe psychiatric illness, cognitive impairment, or any other condition that may interfere with the ability to provide , comply with study treatment, or complete follow-up.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Disitamab Vedotin Plus Toripalimab With Cetirizine and Mecobalamin

    Participants will receive disitamab vedotin 2.0 mg/kg intravenously every 2 weeks and toripalimab 240 mg intravenously every 3 weeks, together with cetirizine 10 mg orally once daily and mecobalamin 0.5 mg orally three times daily. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of a new anticancer therapy, completion of protocol-specified treatment where applicable, or investigator decision. Cetirizine and mecobalamin are administered as a prophylactic/supportive strategy to explore their potential effects on treatment-related peripheral neuropathy and antitumor immune responses.

    Drug: Disitamab Vedotin · Drug: Toripalimab · Drug: Cetirizine · Drug: Mecobalamin

Interventions

  • Disitamab vedotin will be administered intravenously at 2.0 mg/kg every 2 weeks. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of a new anticancer therapy, or investigator decision to discontinue treatment.

  • Toripalimab will be administered intravenously at 240 mg every 3 weeks. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of a new anticancer therapy, completion of protocol-specified treatment, or investigator decision to discontinue treatment.

  • Cetirizine will be administered orally at 10 mg once daily during study treatment as a prophylactic/supportive intervention to explore its potential effects on treatment-related peripheral neuropathy and antitumor immune responses. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of a new anticancer therapy, or investigator decision to discontinue treatment.

  • Mecobalamin will be administered orally at 0.5 mg three times daily during study treatment as a prophylactic/supportive intervention to explore its potential effects on treatment-related peripheral neuropathy. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of a new anticancer therapy, or investigator decision to discontinue treatment.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The proportion of efficacy-evaluable participants whose best overall response is complete response (CR) or partial response (PR), as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. ORR is calculated as the number of participants with CR or PR divided by the total number of efficacy-evaluable participants.

    Time frame: From baseline until disease progression, death, initiation of new anticancer therapy, withdrawal of consent, loss to follow-up, or study completion; assessed every 4 weeks (±7 days).

  2. Incidence of Treatment-Related Grade 2 or Higher Peripheral Neuropathy

    The proportion of participants in the safety analysis population who develop treatment-related Grade 2 or higher peripheral neuropathy during study treatment. Peripheral neuropathy will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 and may include peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, numbness, tingling, pain, burning sensation, hypoesthesia, muscle weakness, impaired fine motor function, or gait instability. Events will be considered treatment-related based on investigator assessment.

    Time frame: From the first dose of study treatment through the end of study treatment.

Secondary outcomes

  1. Incidence of Adverse Events and Serious Adverse Events

    Safety will be assessed by the incidence and severity of adverse events (AEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), adverse drug reactions (ADRs), and immune-related adverse events (irAEs). Adverse events will be graded according to NCI-CTCAE version 5.0. Safety assessments will also include laboratory tests, vital signs, and other clinically relevant safety parameters.

    Time frame: From the first dose through the protocol-defined safety follow-up period; routine safety assessments through 28 days after the last dose, with SAE monitoring through 90 days after the last dose.

  2. Disease Control Rate (DCR)

    The proportion of efficacy-evaluable participants whose best overall response is complete response (CR), partial response (PR), or stable disease (SD), as assessed according to RECIST version 1.1. DCR is calculated as (CR + PR + SD) divided by the total number of efficacy-evaluable participants.

    Time frame: From baseline until disease progression, death, initiation of new anticancer therapy, withdrawal of consent, loss to follow-up, or study completion; assessed every 4 weeks (±7 days).

  3. Progression-Free Survival (PFS)

    PFS is defined as the time from the first administration of study treatment to the first documented radiographic disease progression or death from any cause, whichever occurs first. Participants without progression or death at the time of analysis will be censored at the date of their last evaluable tumor assessment.

    Time frame: From the first administration of study treatment until documented disease progression or death from any cause, whichever occurs first, through study completion.

  4. Overall Survival (OS)

    OS is defined as the time from the first administration of study treatment to death from any cause. Participants who are alive at the time of analysis will be censored at the date they were last known to be alive.

    Time frame: From the first administration of study treatment until death from any cause, through study completion.

Other outcomes

  1. Changes in Tumor, Neuroinflammatory, and Immune Biomarkers

    Exploratory analyses will assess changes in biomarkers related to neural injury or neuroinflammation, HER2 expression, PD-L1 expression, and histamine-H1 receptor signaling. Associations between selected biomarkers and clinical outcomes, including ORR, PFS, OS, treatment response, and peripheral neuropathy, will also be explored.

    Time frame: Baseline and during or after study treatment, through study completion.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Of 65 non-industry phase 1 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 35 months is below that.

Counting every sponsor, half of 145 studies reached it within 43 months; a quarter within 29 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 1, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07853053
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Disitamab vedotin · Toripalimab · Cetirizine · Mecobalamin

Start the discussion